glp-1 obesity drug news october 2025 Eli Lilly set to leapfrog Novo Nordisk in weight-loss race Alarming rise in weight loss

The CV safety of a lower dose of liraglutide (1.8 mg, Victoza, Novo Nordisk) in people with T2D was established in the Liraglutide Effect and Action in Diabetes: Evaluation of CV Outcome Results (LEADER) study, showing a 13% reduction in major CV events over an average of 3.8 years [44]

Despite the promising efficacy and safety data, the market response has been cautious

Foundayo Cost: What to Expect in 2026

Well, it turns out these creepy deep sea monsters have an entire organ for making glucagon, and it was just much easier to dissect that organ out than it was to painstakingly pluck the tiny number of glucagon making cells out of like a mouse's pancreas

R.P., F.G., and S.L